Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regeneron Pharmaceuticals and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Regeneron securities between August 1, 2025 and May 15, 2026. The complaint claims the company made false or misleading statements about its Phase III Fianlimab-Libtayo study, including that preliminary statistical assumptions were fundamentally flawed and the study was unlikely to meet its primary endpoint. Investors have until September 14, 2026 to seek lead plaintiff appointment. The law firm represents investors on a contingency fee basis.
Regeneron Pharmaceuticals IncClass action lawsuit alleging securities law violations and false statements about Phase III study.
